The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients

Figures & data

Figure 1 The different expression of Ki-67 in breast cancer of tumor tissues. ((A) 5%; (B) 20%; (C) 30%; (D) 60%; SP x400).

Figure 2 The frequency distribution of Ki-67 value in 2015–2019.

Table 1 HR+/HER2- Breast Cancer at Different Cut-off Values

Type/Cut-Off Value	14%	22.5%	Kappa	P
Luminal A	320 (33.5%)	585 (61.2%)	0.484	<0.001
Luminal B (HER2-)	636 (66.5%)	371 (38.8%)

Table 2 Correlation of Ki-67 with Pathological for the Different Cut-off Values

Pathological	Ki-67		χ²	P	Ki-67		χ²	P
	<14%	≥14%			<22.5%	≥22.5%
Age			1.458	0.227			8.508	0.004
≤40	40	98			69	69
>40	280	538			516	302
Grade			119.975	<0.001			6.019	0.049
G1	101	54			82	73
G2	196	390			363	223
G3	23	192			140	75
PR expression*			10.046	0.002			27.05	<0.001
≤ 20%	56	170			105	121
>20%	264	466			480	250
T stage			6.468	0.039			7.811	0.020
T1	201	336			352	185
T2	119	282			233	168
T3	5	13			8	10
N stage			5.957	0.114			8.567	0.036
N0	179	310			319	170
N1	89	201			170	120
N2	41	87			72	56
N3	11	38			24	25
Vehicle			5.969	0.015			5.704	0.017
Yes	24	81			53	52
No	296	555			532	319

Note: *References with a PR threshold of 20%.¹⁰

Abbreviations: PR, Progesterone Receptor; χ², Chi-Square Value; P, Probability-value.

Figure 3 The ROC curve of Ki-67 expression (Area under ROC curve: 0.689; Sensitivity: 63.02%; Specificity: 65.57%; Youden Index: 0.286; 95% CI: [0.626–0.754]; P <0.001;).

Figure 4 The relationship between Ki-67 expression and histological grade. (Median: G1:10%; G2:20%; G3:40%. Mean: G1:13%; G2:23%; G3:39%, P <0.001).

Table 3 Univariate Analysis of Prognosis with HR+/HER2- Breast Cancer

Pathological	n	HR	95% CI	χ²	P
Age		1.773	0.9266~3.392	2.992	0.084
≤40	138
>40	818
Ki-67		2.969	1.799~4.901	18.12	<0.0001
Ki-67<22.5%	355
Ki-67≥22.5%	601
Grade		2.220	1.164~4.231	5.867	0.0154
G1	155
G2-3	801
PR expression		0.6075	0.3439~1.073	2.948	0.086
≤ 20%	226
>20%	730
T stage		2.767	1.651~4.635	14.94	0.0001
T1	537
T2-T3	419
N stage		2.464	1.496~4.085	12.55	0.0004
N0	489
N1-N3	467
Vehicle		2.188	1.115~4.294	5.186	0.0228
Yes	851
NO	105

Abbreviations: PR, Progesterone Receptor; HR, Hazard Ratio; CI, Confidence Interval; χ², Chi-Square Value; P, Probability-value.

Table 4 Multivariate Analysis of Prognosis with HR+/HER2- Breast Cancer

Factors	β	SE	Wald	P	HR	95% CI
T stage	0.806	0.264	9.350	0.002	2.239	1.336~3.753
N stage	0.687	0.276	6.198	0.013	1.9889	1.157~3.415
Vehicle	0.456	0.293	2.416	0.120	1.578	0.888~2.805
Grade	0.835	0.537	2.416	0.120	2.306	0.084~6.610
Ki-67	0.866	0.287	9.089	0.003	2.378	1.354~4.178

Abbreviations: β, Beta; SE, Standard Error; P, Probability-value; HR, Hazard Ratio; CI, Confidence Interval.

Figure 5 Kaplan-Meier survival curve with the expression of Ki-67.

Figure 6 The common metastatic sites of HR+/HER2- breast cancer.

Prat A, Cheang MC, Martin M, et al. PPrognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013;31(2):203–209. doi:10.1200/JCO.2012.43.4134

 PubMed Web of Science ®Google Scholar